Steroid resistance in inflammatory bowel diseases: mechanisms of development, physician's tactics in choosing therapy for a patient

Larisa V. Tarasova , Yulia V. Tsyganova

For citation:

Abstract

This review highlights the problem of steroid resistance in the treatment of inflammatory bowel diseases (IBD). The pathway of glucocorticosteroids in the human body, extragenomic and genomic effects of drugs are described in detail. The analysis and systematization of possible models of steroid resistance in IBD are carried out. The need to use current statistical data when choosing drugs for patients with steroid resistance is emphasized. It is determined that the most effective option for selecting therapy, in this case, may be the genetically engineered biological drug ustekinumab.
Key words: steroid resistance, glucocorticosteroids, inflammatory bowel diseases, biological therapy, ustekinumab.

References

1. Белоусова Е.А., Шелыгин Ю.А., Ачкасов С.И. и др. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в Российской Федерации. Первые результаты анализа национального Регистра. Колопроктология. 2023;22(1):65-82. DOI: 10.33878/2073-7556-2023-22-1-65-82

Belousova E.A., Shelygin Yu.A., Achkasov S.I. et al. Clinical and demographic characteristics and therapeutic approaches in patients with inflammatory bowel diseases (Crohn's disease, ulcerative colitis) in the Russian Federation. The first results of the analysis of the national Register. Coloproctology. 2023;22(1):65-82. DOI: 10.33878/2073-7556-2023-22-1-65-82 (in Russian).

2. Князев О.В., Шкурко Т.В., Каграманова А.В. и др. Эпидемиология воспалительных заболеваний кишечника. Современное состояние проблемы (обзор литературы). Доказательная гастроэнтерология. 2020;9(2):66 – 73.

Knyazev O.V., Shkurko T.V., Kagramanova A.V. et al. Epidemiology of inflammatory bowel diseases. The current state of the problem (literature review). Evidence-based gastroenterology. 2020;9(2):66 – 73 (in Russian).

3. Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А. и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;1(83):10-44. DOI: 10.33878/2073-7556-2023-22-1-10-44

Shelygin Yu.A., Ivashkin V.T., Belousova E.A. et al. Ulcerative colitis (K51), adults. Coloproctology. 2023;1(83):10-44. DOI: 10.33878/2073-7556-2023-22-1-10-44 (in Russian).

4. Харитонов А.Г., Щукина О.Б., Кондрашина Э.А. Гормональная резистентность при воспалительных заболеваниях кишечника. Альманах клинической медицины. 2016;44(6):734-43. DOI: 10.18786/2072-0505-2016-44-6-734-743

Kharitonov A.G., Shchukina O.B., Kondrashina E.A. Hormonal resistance in inflammatory bowel diseases. The Almanac of Clinical Medicine. 2016;44(6):734-43. DOI: 10.18786/2072-05-2016-44-6-734-743 (in Russian).

5. Gisbert JP, García MJ, Chaparro M. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review. J Crohns Colitis 2023;17(6):972-994. DOI: 10.1093/ecco-jcc/jjad004

6. Daetwyler E, Wallrabenstein T, König D et al. Corticosteroid-resistant immune-related adverse events: a systematic review. J Immunother Cancer 2024;12(1):e007409. DOI: 10.1136/jitc-2023-007409

7. Revés J, Bravo AC, Nascimento CN et al. Steroid-Refractory Acute Severe Ulcerative Colitis in Infliximab-Experienced Patients. GE Port J Gastroenterol 2024;31(5):314-24. DOI: 10.1159/000537693

8. Головенко О.В., Хомерики С.Г., Иванова Е.В. и др. Воспалительные заболевания кишечника: клинические, эндоскопические, морфологические аспекты диагностики, принципы современной терапии. 2-е издание, доп. и перераб. М.: Прима Принт, 2022.

Golovenko O.V., Khomeriki S.G., Ivanova E.V. et al. Inflammatory bowel diseases: clinical, endoscopic, morphological aspects of diagnosis, principles of modern therapy. 2nd edition, additional and revised, Moscow: Prima Print, 2022 (in Russian).

9. Тодосенко Н.М., Королева Ю.А., Хазиахматова О.Г. и др. Геномные и негеномные эффекты глюкокортикоидов. Гены и клетки. 2017;12(1):27-33. DOI 10.23868/201703003

Todosenko N.M., Koroleva Yu.A., Khaziakhmetova O.G. et al. Genomic and non-genomic effects of glucocorticoids. Genes and cells. 2017;12(1):27-33. DOI 10.23868/201703003 (in Russian).

10. Bamias G, Kokkotis G, Gizis M et al. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Dig Dis Sci 2022;67(3):1007-17. DOI: 10.1007/s10620-021-06907-5

11. Li J, Wang F, Zhang, HJ et al. Corticosteroid therapy in ulcerative colitis: clinical response and predictors. World J Gastroenterol 2015;21:3005-15. DOI: 10.3748/wjg.v21.i10.3005

12. Hasan MM, Tory S. Association between glucocorticoid receptor beta and steroid resistance: A systematic review. Immun Inflamm Dis 2024;12(1):e1137. DOI: 10.1002/iid3.1137

13. Li Q, Liu Y, Li B et al. Bioinformatics analysis of oxidative stress genes in the pathogenesis of ulcerative colitis based on a competing endogenous RNA regulatory network. Peer J 2024;12:e17213. DOI: 10.7717/peerj.17213

14. Liu C, Mo LH, Feng BS et al. Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. Theranostics 2021;11(16):7797-812. DOI: 10.7150/thno.62256

15. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003;178(3):339-46. DOI: 10.1677/joe.0.1780339

16. Zou M, Zeng QS, Nie J et al. The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe? Front Immunol 2021;12:769167. DOI: 10.3389/fimmu.2021.769167

17. Wang S, Pu J, Li X et al. UBE2W Improves the Experimental Colitis by Inhibiting the NF-κB Signaling Pathway. Dig Dis Sci 2022;67(12):5529-5539. DOI: 10.1007/s10620-022-07453-4

18. Gerçeker E, Saygýlý F, Avcý A, Yuceyar H. Steroid Resistance/Dependence Might Be an Alarming Feature for Cytomegalovirus Infection Among Ulcerative Colitis Patients With Increased Disease Activity. Cureus 2022;14(10):e30873. DOI: 10.7759/cureus.30873

19. Wu XW, Wu L, Ji HZ, Wang FY. Relationship Between Cytomegalovirus Infection and Steroid Resistance in Inflammatory Bowel Disease: A Meta-Analysis. Dig Dis Sci 2015;60(11):3203-8. DOI: 10.1007/s10620-015-3733-6

20. Duan S, Yang Y, Cao Y et al. Symptoms of anxiety and depression associated with steroid efficacy and clinical outcomes in patients with inflammatory bowel disease. Front Psychiatry 2023;14:1029467. DOI: 10.3389/fpsyt.2023.1029467

21. Cattaneo A, Ferrari C, Turner L et al. Whole-blood expression of Inflammasome-and glucocorticoid-related Mrnas correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the biodep study. Transl Psychiatry 2020; 10:232. DOI: 10.1038/s41398-020-00874-7

22. Gola H, Engler A, Morath J et al. Reduced peripheral expression of the glucocorticoid receptor alpha isoform in individuals with posttraumatic stress disorder: a cumulative effect of trauma burden. PLoS One 2014;9:e86333. DOI: 10.1371/journal.pone.0086333

23. Alam MF, Longo M, Cohen D et al. Infliximab versus ciclosporin in steroid resistant acute severe ulcerative colitis: a model-based cost-utility analysis of data from CONSTRUCT pragmatic trial. BMC Health Serv Res 2023;23(1):226. DOI: 10.1186/s12913-023-09233-w

24. Yu S, Li H, Li Y et al. Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning. Gastroenterol Rep (Oxf) 2022;10:goac053. DOI: 10.1093/gastro/goac053

25. Komeda Y, Tribonias G, Kono M et al. Real-World Data on Short-Term and Long-Term Treatment Results of Ustekinumab in Patients with Steroid-Resistant/Dependent Ulcerative Colitis. Inflamm Intest Dis 2023;8(4):161-66. DOI: 10.1159/000534457

For citation:Tarasova L.V., Tsyganova Yu.V. Steroid resistance in inflammatory bowel diseases: mechanisms of development, physician's tactics in choosing therapy for a patient. Clinical review for general practice. 2025; 6 (1): 41–44 (In Russ.). DOI: 10.47407/kr2024.6.1.00548

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice